RZLT

Rezolute, Inc. Common Stock (NV)

3.25

USD

RZLT Earnings Reports

Positive Surprise Ratio

RZLT beat 17 of 27 last estimates.

63%

Next Report

Date of Next Report

May 11, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$0.17

Implied change from Q2 26 (Revenue/ EPS)

-22.73%

Implied change from Q3 25 (Revenue/ EPS)

-37.04%

Rezolute, Inc. Common Stock (NV) earnings per share and revenue

On Feb 12, 2026, RZLT reported earnings of -0.22 USD per share (EPS) for Q2 26, missing the estimate of -0.19 USD, resulting in a -15.36% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.79% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 12 analysts forecast an EPS of -0.17 USD, with revenue projected to reach -- USD, implying an decrease of -22.73% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.41

Surprise

+11.29%

Spero Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.20

Actual

$0.53

Surprise

+359.80%

Rani Therapeutics Holdings, Inc. Class A Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-2.94%

Alpha Cognition Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-8.93%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

Cognition Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.02

Surprise

+76.47%

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

Actual

-$0.71

Surprise

CollPlant Biotechnologies Ltd Ordinary Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.67

Surprise

-245.72%

FAQ

What were Rezolute, Inc. Common Stock (NV)'s earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Rezolute, Inc. Common Stock (NV) reported EPS of -$0.22, missing estimates by -15.36%, and revenue of $0.00, 0% as expectations.

How did the market react to Rezolute, Inc. Common Stock (NV)'s Q2 2026 earnings?

The stock price moved up 5.79%, changed from $3.63 before the earnings release to $3.84 the day after.

When is Rezolute, Inc. Common Stock (NV) expected to report next?

The next earning report is scheduled for May 11, 2026.

What are the forecasts for Rezolute, Inc. Common Stock (NV)'s next earnings report?

Based on 12 analysts, Rezolute, Inc. Common Stock (NV) is expected to report EPS of -$0.17 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.